Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones

Background and Objectives Chalcone constitutes one of the most used molecular frameworks in medicinal chemistry and its derivatives exhibit a broad spectrum of biological activities. Low absolute bioavailability, poor distribution, intensive metabolism and elimination of chalcones are the main probl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of drug metabolism and pharmacokinetics 2017-02, Vol.42 (1), p.49-58
Hauptverfasser: Okoniewska, Krystyna, Konieczny, Marek T., Lemke, Krzysztof, Grabowski, Tomasz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 58
container_issue 1
container_start_page 49
container_title European journal of drug metabolism and pharmacokinetics
container_volume 42
creator Okoniewska, Krystyna
Konieczny, Marek T.
Lemke, Krzysztof
Grabowski, Tomasz
description Background and Objectives Chalcone constitutes one of the most used molecular frameworks in medicinal chemistry and its derivatives exhibit a broad spectrum of biological activities. Low absolute bioavailability, poor distribution, intensive metabolism and elimination of chalcones are the main problems in designing new drugs based on their structure. One of the fundamental steps in evaluation of drug candidates is a comparative analysis of pharmacokinetic parameters. The aim of the studies was the pharmacokinetic characterization of the selected oxathio-heterocycle fused chalcones. Methods The pharmacokinetic parameters of 19 compounds were reported. The analyzed chalcones were examined after a single intravenous administration to forty 7-week-old mature male rats of Wistar stock. Pharmacokinetic analysis was performed independently using SHAM (slopes, highest, amounts, and moments) and the two-compartment model. Basic physiochemical parameters were calculated. The bioanalytical methods were validated in terms of repeatability, linearity, accuracy, precision, and selectivity. Results The pharmacokinetics of the examined group of chalcones are compatible with the two-compartment model. The physicochemical characteristics of this group are quite homogeneous. The kinetics of the examined chalcones are indicative of a distribution to the tissue compartment with the predominance of a rate constant from central to peripheral compartments (k 12 ) over the rate constant from peripheral to central compartments (k 21 ). The elimination from the central compartment (k 10 ) is higher than the transfer from the central compartment to the tissues (k 10  > k 12 ) in almost all examined cases. Conclusions The presented group of compounds may form a starting point for studies into drugs treating autoimmune diseases of the gastro-intestinal tract.
doi_str_mv 10.1007/s13318-016-0320-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826653798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826653798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-713ae34ac87fe9948cdddca9670e31303451e768de1c7324572873db2e7479263</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbKn9AV4kRy_R_Uh2NxdBirWCUEE9L9vdiU1NsnU3AfPv3ZLq0bkMzDzzwjwIXRJ8QzAWt4EwRmSKCU8xozgdTtCUEiziROJTNMVMyFQUnE_QPIQdjsVkkef8HE0olyTPCzxFdy9b7Rtt3GfVQleZ5LXrbQUhcWWy_tbdtnLpCjrwzgymhmTZB7DJYqtr41oIF-is1HWA-bHP0Pvy4W2xSp_Xj0-L--fUsCzrUkGYBpZpI0UJRZFJY601uuACAyMMsywnILi0QIxgNMsFlYLZDQWRiYJyNkPXY-7eu68eQqeaKhioa92C64MiknKeM1HIiJIRNd6F4KFUe1812g-KYHUwp0ZzKppTB3NqiDdXx_h-04D9u_j1FAE6AiGu2g_waud638aX_0n9AZz6d_4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826653798</pqid></control><display><type>article</type><title>Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Okoniewska, Krystyna ; Konieczny, Marek T. ; Lemke, Krzysztof ; Grabowski, Tomasz</creator><creatorcontrib>Okoniewska, Krystyna ; Konieczny, Marek T. ; Lemke, Krzysztof ; Grabowski, Tomasz</creatorcontrib><description>Background and Objectives Chalcone constitutes one of the most used molecular frameworks in medicinal chemistry and its derivatives exhibit a broad spectrum of biological activities. Low absolute bioavailability, poor distribution, intensive metabolism and elimination of chalcones are the main problems in designing new drugs based on their structure. One of the fundamental steps in evaluation of drug candidates is a comparative analysis of pharmacokinetic parameters. The aim of the studies was the pharmacokinetic characterization of the selected oxathio-heterocycle fused chalcones. Methods The pharmacokinetic parameters of 19 compounds were reported. The analyzed chalcones were examined after a single intravenous administration to forty 7-week-old mature male rats of Wistar stock. Pharmacokinetic analysis was performed independently using SHAM (slopes, highest, amounts, and moments) and the two-compartment model. Basic physiochemical parameters were calculated. The bioanalytical methods were validated in terms of repeatability, linearity, accuracy, precision, and selectivity. Results The pharmacokinetics of the examined group of chalcones are compatible with the two-compartment model. The physicochemical characteristics of this group are quite homogeneous. The kinetics of the examined chalcones are indicative of a distribution to the tissue compartment with the predominance of a rate constant from central to peripheral compartments (k 12 ) over the rate constant from peripheral to central compartments (k 21 ). The elimination from the central compartment (k 10 ) is higher than the transfer from the central compartment to the tissues (k 10  &gt; k 12 ) in almost all examined cases. Conclusions The presented group of compounds may form a starting point for studies into drugs treating autoimmune diseases of the gastro-intestinal tract.</description><identifier>ISSN: 0378-7966</identifier><identifier>EISSN: 2107-0180</identifier><identifier>DOI: 10.1007/s13318-016-0320-y</identifier><identifier>PMID: 26815590</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Administration, Intravenous ; Animals ; Biomedical and Life Sciences ; Biomedicine ; Chalcones - administration &amp; dosage ; Chalcones - pharmacokinetics ; Data Accuracy ; Human Physiology ; Male ; Medical Biochemistry ; Models, Biological ; Original Research Article ; Pharmaceutical Sciences/Technology ; Pharmacology/Toxicology ; Pharmacy ; Rats ; Rats, Wistar ; Reproducibility of Results</subject><ispartof>European journal of drug metabolism and pharmacokinetics, 2017-02, Vol.42 (1), p.49-58</ispartof><rights>Springer International Publishing Switzerland 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-713ae34ac87fe9948cdddca9670e31303451e768de1c7324572873db2e7479263</citedby><cites>FETCH-LOGICAL-c344t-713ae34ac87fe9948cdddca9670e31303451e768de1c7324572873db2e7479263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13318-016-0320-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13318-016-0320-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27926,27927,41490,42559,51321</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26815590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okoniewska, Krystyna</creatorcontrib><creatorcontrib>Konieczny, Marek T.</creatorcontrib><creatorcontrib>Lemke, Krzysztof</creatorcontrib><creatorcontrib>Grabowski, Tomasz</creatorcontrib><title>Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones</title><title>European journal of drug metabolism and pharmacokinetics</title><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><description>Background and Objectives Chalcone constitutes one of the most used molecular frameworks in medicinal chemistry and its derivatives exhibit a broad spectrum of biological activities. Low absolute bioavailability, poor distribution, intensive metabolism and elimination of chalcones are the main problems in designing new drugs based on their structure. One of the fundamental steps in evaluation of drug candidates is a comparative analysis of pharmacokinetic parameters. The aim of the studies was the pharmacokinetic characterization of the selected oxathio-heterocycle fused chalcones. Methods The pharmacokinetic parameters of 19 compounds were reported. The analyzed chalcones were examined after a single intravenous administration to forty 7-week-old mature male rats of Wistar stock. Pharmacokinetic analysis was performed independently using SHAM (slopes, highest, amounts, and moments) and the two-compartment model. Basic physiochemical parameters were calculated. The bioanalytical methods were validated in terms of repeatability, linearity, accuracy, precision, and selectivity. Results The pharmacokinetics of the examined group of chalcones are compatible with the two-compartment model. The physicochemical characteristics of this group are quite homogeneous. The kinetics of the examined chalcones are indicative of a distribution to the tissue compartment with the predominance of a rate constant from central to peripheral compartments (k 12 ) over the rate constant from peripheral to central compartments (k 21 ). The elimination from the central compartment (k 10 ) is higher than the transfer from the central compartment to the tissues (k 10  &gt; k 12 ) in almost all examined cases. Conclusions The presented group of compounds may form a starting point for studies into drugs treating autoimmune diseases of the gastro-intestinal tract.</description><subject>Administration, Intravenous</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Chalcones - administration &amp; dosage</subject><subject>Chalcones - pharmacokinetics</subject><subject>Data Accuracy</subject><subject>Human Physiology</subject><subject>Male</subject><subject>Medical Biochemistry</subject><subject>Models, Biological</subject><subject>Original Research Article</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reproducibility of Results</subject><issn>0378-7966</issn><issn>2107-0180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1Lw0AQhhdRbKn9AV4kRy_R_Uh2NxdBirWCUEE9L9vdiU1NsnU3AfPv3ZLq0bkMzDzzwjwIXRJ8QzAWt4EwRmSKCU8xozgdTtCUEiziROJTNMVMyFQUnE_QPIQdjsVkkef8HE0olyTPCzxFdy9b7Rtt3GfVQleZ5LXrbQUhcWWy_tbdtnLpCjrwzgymhmTZB7DJYqtr41oIF-is1HWA-bHP0Pvy4W2xSp_Xj0-L--fUsCzrUkGYBpZpI0UJRZFJY601uuACAyMMsywnILi0QIxgNMsFlYLZDQWRiYJyNkPXY-7eu68eQqeaKhioa92C64MiknKeM1HIiJIRNd6F4KFUe1812g-KYHUwp0ZzKppTB3NqiDdXx_h-04D9u_j1FAE6AiGu2g_waud638aX_0n9AZz6d_4</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Okoniewska, Krystyna</creator><creator>Konieczny, Marek T.</creator><creator>Lemke, Krzysztof</creator><creator>Grabowski, Tomasz</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones</title><author>Okoniewska, Krystyna ; Konieczny, Marek T. ; Lemke, Krzysztof ; Grabowski, Tomasz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-713ae34ac87fe9948cdddca9670e31303451e768de1c7324572873db2e7479263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Intravenous</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Chalcones - administration &amp; dosage</topic><topic>Chalcones - pharmacokinetics</topic><topic>Data Accuracy</topic><topic>Human Physiology</topic><topic>Male</topic><topic>Medical Biochemistry</topic><topic>Models, Biological</topic><topic>Original Research Article</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okoniewska, Krystyna</creatorcontrib><creatorcontrib>Konieczny, Marek T.</creatorcontrib><creatorcontrib>Lemke, Krzysztof</creatorcontrib><creatorcontrib>Grabowski, Tomasz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of drug metabolism and pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okoniewska, Krystyna</au><au>Konieczny, Marek T.</au><au>Lemke, Krzysztof</au><au>Grabowski, Tomasz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones</atitle><jtitle>European journal of drug metabolism and pharmacokinetics</jtitle><stitle>Eur J Drug Metab Pharmacokinet</stitle><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>42</volume><issue>1</issue><spage>49</spage><epage>58</epage><pages>49-58</pages><issn>0378-7966</issn><eissn>2107-0180</eissn><abstract>Background and Objectives Chalcone constitutes one of the most used molecular frameworks in medicinal chemistry and its derivatives exhibit a broad spectrum of biological activities. Low absolute bioavailability, poor distribution, intensive metabolism and elimination of chalcones are the main problems in designing new drugs based on their structure. One of the fundamental steps in evaluation of drug candidates is a comparative analysis of pharmacokinetic parameters. The aim of the studies was the pharmacokinetic characterization of the selected oxathio-heterocycle fused chalcones. Methods The pharmacokinetic parameters of 19 compounds were reported. The analyzed chalcones were examined after a single intravenous administration to forty 7-week-old mature male rats of Wistar stock. Pharmacokinetic analysis was performed independently using SHAM (slopes, highest, amounts, and moments) and the two-compartment model. Basic physiochemical parameters were calculated. The bioanalytical methods were validated in terms of repeatability, linearity, accuracy, precision, and selectivity. Results The pharmacokinetics of the examined group of chalcones are compatible with the two-compartment model. The physicochemical characteristics of this group are quite homogeneous. The kinetics of the examined chalcones are indicative of a distribution to the tissue compartment with the predominance of a rate constant from central to peripheral compartments (k 12 ) over the rate constant from peripheral to central compartments (k 21 ). The elimination from the central compartment (k 10 ) is higher than the transfer from the central compartment to the tissues (k 10  &gt; k 12 ) in almost all examined cases. Conclusions The presented group of compounds may form a starting point for studies into drugs treating autoimmune diseases of the gastro-intestinal tract.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26815590</pmid><doi>10.1007/s13318-016-0320-y</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-7966
ispartof European journal of drug metabolism and pharmacokinetics, 2017-02, Vol.42 (1), p.49-58
issn 0378-7966
2107-0180
language eng
recordid cdi_proquest_miscellaneous_1826653798
source MEDLINE; SpringerNature Journals
subjects Administration, Intravenous
Animals
Biomedical and Life Sciences
Biomedicine
Chalcones - administration & dosage
Chalcones - pharmacokinetics
Data Accuracy
Human Physiology
Male
Medical Biochemistry
Models, Biological
Original Research Article
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Pharmacy
Rats
Rats, Wistar
Reproducibility of Results
title Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T03%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20Studies%20of%20Oxathio-Heterocycle%20Fused%20Chalcones&rft.jtitle=European%20journal%20of%20drug%20metabolism%20and%20pharmacokinetics&rft.au=Okoniewska,%20Krystyna&rft.date=2017-02-01&rft.volume=42&rft.issue=1&rft.spage=49&rft.epage=58&rft.pages=49-58&rft.issn=0378-7966&rft.eissn=2107-0180&rft_id=info:doi/10.1007/s13318-016-0320-y&rft_dat=%3Cproquest_cross%3E1826653798%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826653798&rft_id=info:pmid/26815590&rfr_iscdi=true